Detection and characterization of immunoconglutinins in patients with systemic lupus erythematosus (SLE): serial analysis in relation to disease course

The levels of IgA, IgG and IgM immunoconglutinins (IK) were assessed in sera from 20 patients with SLE which were followed for 8‐month periods. At the time of the exacerbation, IgG IKs were significantly increased to 226 ± 90 arbitrary units (mean ± s.e.m.) compared with both the minimum value of 75 ± 28 in the SLE patients and with 31 ± 2 in healthy controls (P <0±05). There was no difference between SLE patients and controls in the levels of IgM and IgA IKs. Most of the SLE patients in this material showed maximal IgG IK levels before exacerbation, but there was no correlation between the clinical disease index and the levels of IgG IK. The specificity of IgG IKs showed a broad diversity for microtitre‐fixed C3b, iC3b, C3c and C3dg. The antibodies were of IgG1, IgG3 and in two patients, IgG4 subclass. IgG IKs were correlated to the C3d/C3 ratio which suggested that the IK responses were secondary to C3 activation. In summary, unlike other conditions associated with complement activation where elevated IgM IKs are common, an increase in IgG IK levels was observed. It is possible that this diverging IK response contributes to the pathophysiology of the disease.

[1]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[2]  G. Füst,et al.  The role of C3 in the immune response. , 1991, Immunology today.

[3]  J. Bonnetblanc,et al.  The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. , 1991, The Journal of investigative dermatology.

[4]  P. Limburg,et al.  Predominance of IgGl and IgG4 subclasses of anti‐neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders , 1991, Clinical and experimental immunology.

[5]  B. Nilsson,et al.  Purification and characterization of IgG immunoconglutinins from patien with systemic lupus erythematosus: implications for a regulatory functiot , 1990, Clinical and experimental immunology.

[6]  K. Sayama,et al.  Subclass Characteristics of IgG Autoantibodies in Bullous Pemphigoid and Pemphigus , 1990, The Journal of dermatology.

[7]  B. Nilsson,et al.  Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I. , 1990, Journal of immunology.

[8]  J. Nossent,et al.  Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance. , 1989, Annals of the rheumatic diseases.

[9]  M. Brüggemann,et al.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q , 1988, The Journal of experimental medicine.

[10]  P. Wooley,et al.  Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis. Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a. , 1986, Arthritis and rheumatism.

[11]  C. Durand,et al.  A new enzyme-linked immunosorbent assay (ELISA) for measuring immunoconglutinins directed against the third component of human complement. Findings in systemic lupus erythematosus. , 1984, Journal of immunological methods.

[12]  A. Sjöholm,et al.  Complement components, complement activation, and acute phase response in systemic lupus erythematosus. , 1984, International archives of allergy and applied immunology.

[13]  R. Maini,et al.  Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. , 1982, Journal of immunological methods.

[14]  H. Gresham,et al.  Large scale isolation of functionally active components of the human complement system. , 1981, The Journal of biological chemistry.

[15]  M. Pepys,et al.  Radioimmunoassay for immunoconglutinins. , 1980, Journal of immunological methods.

[16]  T. Barkas,et al.  Biological activities of complement. , 1978, Biochemical Society transactions.

[17]  J. Bienenstock,et al.  Immunoconglutinin in various rheumatic diseases and certain diseases suspected of an autoimmune pathogenesis. , 1967, Arthritis and rheumatism.

[18]  C. Laurell,et al.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.

[19]  Orstavik Kh Inhibitors to factor IX contain all IgG subclasses except IgG3. , 1990 .

[20]  P. Lachmann Conglutinin and immunoconglutinins. , 1967, Advances in immunology.